Beta Blocker Interruption After Uncomplicated Myocardial Infarction (AβYSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03498066

Recruitment Status : Completed

First Posted : April 13, 2018

Last Update Posted : December 6, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Groupe Hospitalier Pitie-Salpetriere

Information provided by (Responsible Party):

Assistance Publique - Hôpitaux de Paris

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	October 31, 2023
Actual Study Completion Date :	October 31, 2023

Publications of Results:

Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, Collet JP, Dumaine R, Slama M, Payot L, Kasty ME, Aacha K, Vicaut E, Montalescot G; ABYSS investigators of the ACTION Study Group,. betaeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial. Am Heart J. 2023 Apr;258:168-176. doi: 10.1016/j.ahj.2023.01.014. Epub 2023 Jan 20.

To Top